Understanding the Scope of Vaping During Pregnancy

The prevalence of vaping during pregnancy has increased notably across global populations in recent years. Many patients mistakenly assume that electronic nicotine delivery systems offer a completely harmless alternative to conventional cigarettes. However, accumulating clinical and experimental investigations demonstrate a much more complex and concerning reality. A comprehensive scoping review by Fielder and colleagues evaluated sixty-four published investigations to map the current evidence landscape. Consequently, their synthesis revealed critical insights regarding maternal, fetal, and infant health outcomes following gestational aerosol exposure. The authors analyzed thirty human observational studies alongside thirty-four preclinical animal experiments. Furthermore, they identified profound disparities between clinical observational findings and laboratory animal models. Most human studies focused narrowly on immediate birth outcomes while largely overlooking maternal vascular and autonomic dynamics. In contrast, preclinical models demonstrated broad biological disruptions across multiple organ systems. Therefore, obstetricians and primary care clinicians must comprehend both evidence bases to counsel expectant mothers effectively. While patients often perceive vaping as a harmless bridge toward tobacco cessation, nicotine remains a potent teratogen. Ultimately, understanding these complex scientific findings enables maternity teams to communicate gestational risks clearly and compassionately.

Human Clinical Evidence and Methodological Limitations

Human observational studies form an essential foundation for clinical understanding, yet significant methodological limitations persist across the published literature. Crucially, the scoping review revealed that most human studies relied entirely on retrospective maternal self-reporting without biochemical validation. Because nicotine use carries considerable social stigma, self-reporting frequently underestimates actual gestational consumption. Furthermore, lack of cotinine or anabasine testing prevents researchers from verifying exposure timing and cumulative dosage. In addition, many observational cohorts included participants who engaged in dual use by combining electronic cigarettes with combustible tobacco. This concurrent exposure creates severe confounding, making it impossible to isolate the specific physiological sequelae of vaping aerosols. Moreover, clinical investigators frequently compared vaping cohorts against conventional cigarette smokers rather than non-tobacco controls. This comparative design obscures baseline harm because smoking already carries extreme perinatal hazards. Human studies also restricted their evaluations primarily to perinatal endpoints such as birth weight, gestational age, and preterm delivery. Consequently, maternal physiological endpoints, such as arterial stiffness, vascular endothelial function, and metabolic parameters, remain almost entirely unmeasured. These persistent methodological weaknesses highlight why existing human epidemiological studies cannot definitively quantify individual risk profiles.

Mechanistic Insights from Preclinical Animal Models

Preclinical animal models provide direct mechanistic clarity that human observational studies cannot achieve due to ethical constraints. In the scoping review, thirty-four animal experiments evaluated specific organ networks following maternal e-cigarette exposure. Specifically, rodent models demonstrated marked vascular dysfunction, heightened oxidative stress, and structural endothelial damage in response to aerosol inhalation. Furthermore, pregnant dams exposed to nicotine-containing aerosols exhibited significant reductions in uterine blood flow and placental perfusion. These vascular impairments directly contributed to intrauterine growth restriction and reduced neonatal pup weight. Animal investigations also explored long-term neurodevelopmental sequelae, uncovering altered synaptic plasticity and modified neurobehavioral responses in mature offspring. In addition, experimental studies documented lasting pulmonary impairment, including abnormal alveolar septation and heightened airway hyperresponsiveness in neonates. Importantly, nicotine-rich aerosols caused substantially greater tissue injury than nicotine-free carrier solutions. This observation confirms that nicotine acts as an independent vascular and neural toxicant in developing fetuses. However, clinicians must interpret preclinical conclusions with appropriate prudence. Laboratory exposure chambers frequently subject rodents to continuous aerosol concentrations that exceed normal human vaping behaviors. In addition, physiological differences in placental anatomy prevent direct translation to pregnant women.

Maternal Physiological Impacts and Neglected Research Gaps

A striking finding identified by the scoping review is the profound neglect of maternal physiological monitoring across clinical studies. Although clinicians recognize maternal health as the cornerstone of fetal well-being, existing trials rarely assessed maternal physiology. For example, clinical researchers almost never evaluated pulse wave velocity, continuous central blood pressure, or endothelial activation markers among pregnant vapers. Instead, human investigations limited maternal assessments to subjective reports of gestational weight gain, postpartum depressive symptoms, or breastfeeding duration. Consequently, medical teams currently lack vital evidence regarding maternal vascular resistance, preeclampsia vulnerability, and cardiac hemodynamics during e-cigarette use. Furthermore, substantial discordance exists between animal findings and clinical studies. Preclinical models demonstrate that e-cigarette aerosols trigger marked autonomic imbalance, vascular oxidative stress, and inflammatory cascades in the mother. However, clinical cohorts have not yet measured these physiological parameters in human pregnancies. Researchers also must evaluate the toxicological role of carrier liquids like propylene glycol and vegetable glycerin. When heated, these humectants degrade into dangerous aldehydes that exacerbate systemic oxidative stress independently of nicotine. Therefore, future clinical research must integrate prospective physiological monitoring with comprehensive chemical analysis to understand maternal vascular consequences fully.

Clinical Practice Guidance and Policy Recommendations

The findings from this scoping review emphasize an urgent need for proactive clinical leadership in obstetric care. Because many expectant parents believe electronic devices eliminate toxic exposure, clinicians must actively correct these dangerous misconceptions. The American College of Obstetricians and Gynecologists explicitly recommends against using e-cigarettes during pregnancy and the postpartum period. Obstetricians should screen every pregnant patient for all forms of nicotine consumption, including vaping, at every prenatal visit. Furthermore, clinicians must communicate that nicotine readily traverses the placental syncytiotrophoblast, disrupting fetal cerebral maturation and vascular development. In jurisdictions like India, the Prohibition of Electronic Cigarettes Act legally prohibits e-cigarette commercialization. Nevertheless, clinicians frequently manage patients who obtain illicit or unregulated devices online. When patients report vaping, healthcare teams should offer compassionate, non-punitive cessation counseling. Clinicians should establish structured behavioral support as the first-line therapeutic intervention for nicotine cessation. If behavioral counseling proves inadequate, clinicians may consider regulated pharmacotherapy, such as standard nicotine replacement therapy, under shared clinical decision-making. Ultimately, establishing clear public health policies and rigorous prospective studies will protect vulnerable mothers and their infants from preventable harm.

Frequently Asked Questions

Is vaping during pregnancy safer than smoking conventional cigarettes?

While e-cigarettes emit fewer combustion products than combustible cigarettes, vaping is not safe during pregnancy. Aerosols still deliver nicotine, heavy metals, and toxic aldehydes directly to maternal and fetal circulations. Nicotine constricts placental vessels and disrupts fetal neurodevelopment. Therefore, clinical guidelines advise pregnant individuals to avoid all electronic nicotine delivery systems.

Can pregnant individuals use e-cigarettes as a smoking cessation tool?

Major professional bodies, including the American College of Obstetricians and Gynecologists, do not recommend e-cigarettes for gestational smoking cessation. Robust evidence demonstrating their safety and efficacy during pregnancy remains absent. Instead, clinicians prioritize structured behavioral counseling. If behavioral strategies fail, providers evaluate licensed nicotine replacement therapies with established safety profiles under strict clinical supervision.

What biological consequences do preclinical animal studies reveal about gestational vaping?

Preclinical animal models reveal that gestational aerosol exposure triggers substantial maternal vascular dysfunction, systemic oxidative stress, and impaired placental perfusion. Furthermore, exposed offspring display restricted intrauterine growth, abnormal alveolar development, and altered neurobehavioral functioning. Nicotine-containing aerosols produce significantly more severe multi-organ pathology than nicotine-free solutions, demonstrating the direct developmental toxicity of aerosolized nicotine.

Disclaimer: This content is for informational and educational purposes only and should not be taken as professional medical advice. Healthcare professionals must evaluate clinical decisions independently. Refer to the latest local and national guidelines for clinical practice.

References

• Fielder S et al. Vaping during pregnancy and maternal, fetal, and infant health outcomes: A scoping review of human and animal studies. PLoS One. 2026. doi: 10.1371/journal.pone.0356305. PMID: 42809573.


• American College of Obstetricians and Gynecologists. Tobacco and Nicotine Cessation During Pregnancy: ACOG Committee Opinion, Number 807. Obstet Gynecol. 2020;135(5):e221-e229.


• Royal College of Obstetricians and Gynaecologists. Smoking and pregnancy: Patient information and clinical advice. RCOG Guidelines. 2020; London: RCOG.